ArticleAntimicrobial agents and chemotherapy2022
Mutagenesis and Resistance Development of Bacteria Challenged by Silver Nanoparticles.
Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Integrating silver nanomaterials in wound healing: from physicochemical properties to clinical translation.Journal of nanobiotechnology · 2026Review
- Rapid Evolution of Ionic Silver Resistance inMicroorganisms · 2026Article
- Bioinformatic Resistome Profiling of Metal Tolerance Mechanisms in Endodontic Infections: Implications for Antimicrobial Nanoparticle-Based Biomaterials.Journal of functional biomaterials · 2026Article
- Inhibitory activity of silver nanoparticles on Staphylococcus aureus growth and α-hemolysin gene expression.Molecular biology reports · 2026Article
- Emerging strategies of bacterial adaptation mechanisms to silver and metal oxide nanomaterials.FEMS microbiology reviews · 2026Review
- Challenges Associated With the Use of Metal and Metal Oxide Nanoparticles as Antimicrobial Agents: A Review of Resistance Mechanisms and Environmental Implications.Biotechnology journal · 2025Review
- Potential Antibiotic Resurgence: Consecutive Silver Nanoparticle Applications Gradually Increase Bacterial Susceptibility to Antibiotics.ACS omega · 2025Article
- Advances in nanomaterial-mediated CRISPR/Cas delivery: from lipid nanoparticles to vesicle-derived systems.Frontiers in bioengineering and biotechnology · 2025Review
- Green Silver Nanoparticles: An Antibacterial Mechanism.Antibiotics (Basel, Switzerland) · 2024Review
- Article
- Article
- Therapeutic Potential of Silver Nanoparticles (AgNPs) as an Antimycobacterial Agent: A Comprehensive Review.Antibiotics (Basel, Switzerland) · 2024Review
- SilversolPharmaceutics · 2024Article
- Silver nanoparticles elevate mutagenesis of eukaryotic genomes.G3 (Bethesda, Md.) · 2023Article
- Metals to combat antimicrobial resistance.Nature reviews. Chemistry · 2023Review
- Emergence of microbial resistance against nanoparticles: Mechanisms and strategies.Frontiers in microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
Abstract
Because of their extremely broad spectrum and strong biocidal power, nanoparticles of metals, especially silver (AgNPs), have been widely applied as effective antimicrobial agents against bacteria, fungi, and so on. However, the mutagenic effects of AgNPs and resistance mechanisms of target cells remain controversial. In this study, we discover that AgNPs do not speed up resistance mutation generation by accelerating genome-wide mutation rate of the target bacterium Escherichia coli. AgNPs-treated bacteria also show decreased expression in quorum sensing (QS), one of the major mechanisms leading to population-level drug resistance in microbes. Nonetheless, these nanomaterials are not immune to resistance development by bacteria. Gene expression analysis, experimental evolution in response to sublethal or bactericidal AgNPs treatments, and gene editing reveal that bacteria acquire resistance mainly through two-component regulatory systems, especially those involved in metal detoxification, osmoregulation, and energy metabolism. Although these findings imply low mutagenic risks of nanomaterial-based antimicrobial agents, they also highlight the capacity for bacteria to evolve resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.